Why does EGFR-targeted therapy continue to fail in breast cancer? From mechanistic deciphering to novel intervention...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) is overexpressed in certain breast cancers, including triple-negative breast cancer (TNBC) and endocrine-resistant types, making it a potential therapeutic target.
• Despite success in other cancers, EGFR inhibitors show limited efficacy in breast cancer due to resistance mechanisms, such as compensatory pathway activation and abnormal protein stability.
• This resistance leads to insufficient therapeutic responses, highlighting the need for alternative treatment strategies.

Purpose of the Study:

• To review protein-targeted degradation technologies as a novel approach to overcome EGFR inhibitor resistance in breast cancer.
• To discuss the potential of Proteolysis-Targeting Chimeras (PROTAC) and Lysosome-Targeting Chimeras (LYTAC) in degrading EGFR proteins.
• To identify future research directions for improving treatment outcomes in EGFR-overexpressing breast cancer.

Main Methods:

• Review of existing literature on EGFR inhibitors, resistance mechanisms in breast cancer, and protein-targeted degradation technologies.
• Discussion of PROTAC and LYTAC mechanisms for inducing protein degradation via ubiquitin-proteasome or lysosomal pathways.
• Analysis of potential strategies to circumvent resistance to traditional small-molecule EGFR inhibitors.

Main Results:

• Protein-targeted degradation technologies, including PROTAC and LYTAC, offer a promising strategy to directly induce EGFR protein degradation.
• These novel approaches can bypass resistance mechanisms associated with traditional EGFR inhibitors.
• Successful application of these technologies could lead to improved therapeutic responses in EGFR-overexpressing breast cancers.

Conclusions:

• Protein-targeted degradation presents a novel therapeutic avenue for overcoming resistance to EGFR inhibitors in breast cancer.
• Future research should focus on precision molecular subtyping for patient selection and understanding resistance mechanisms.
• Exploring novel combination therapies and optimizing patient selection are crucial for developing effective, individualized treatments for EGFR-overexpressing breast cancer.